Century Therapeutics (IPSC) stock
IPSC's Quality Score was unchanged on Tue, Oct 6, at -2.
Follow IPSC's trial news. Pro members can get an alert when Century Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
Moves 9.1% a day with no recent filing behind it.
3 more reasons behind IPSC's -2, for Pro members
What's next for IPSC, and how long its cash lasts
From Century Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 9 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Jul 10, 2025)
- At-the-market share sales program (424B5, filed Mar 26, 2026)
Insiders
An officer, Gregory Russotti, sold 2,587 shares on Sep 14. 14 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 36% in 3 months, 24% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 15% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over two years
2 more things pulling IPSC's score down, for Pro members
What's next
Fri Oct 9: Breakthrough T1D Clinical…Industry event · date confirmed.
Expected to report Thu Nov 12, before the open
After its last 4 reports it closed -7.8% on average, higher 0 of 4 times.
What would turn IPSC's score around: 5 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
IPSC has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1421.1
- MACD (12, 26, 9)Below signal
- 50-day average$1.93
- 200-day average$2.08
- ADX 1429.8
- Support$0.90
- Resistance$2.25
- Volume5.0x
How IPSC ranks in Biotech
IPSC is #178 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
IONSOpen for its score
IOVAOpen for its score
IQVOpen for its score
IRONOpen for its score
IPSC1/14-2
When does IPSC report earnings, and what happens after?
Expected to report Thu Nov 12, before the open (in 37 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026Before open | Before open | +1.0% | -4.8% | -4.8% |
| May 13, 2026Before open | Before open | +0.4% | -0.4% | -7.4% |
| Mar 12, 2026Before open | Before open | +6.2% | -8.4% | -15.8% |
| Nov 13, 2025Before open | Before open | -5.9% | -17.5% | -8.2% |
Who is trading IPSC
IPSC insider trades
2 insiders sold $21K across 9 filings in the last 6 months. No open-market buys on record. The newest:
IPSC's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of IPSC's score, with the points and the reason
- All 14 checks on IPSC and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on IPSC
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.